Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Tufted hair folliculitis in a woman treated with trastuzumab.

Rosman IS, Anadkat MJ.

Target Oncol. 2010 Dec;5(4):295-6. doi: 10.1007/s11523-010-0162-5. Epub 2010 Oct 15.

PMID:
20949375
2.

Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.

Ena P, Fadda GM, Ena L, Farris A, Santeufemia DA.

Clin Exp Dermatol. 2008 Nov;33(6):790-1. doi: 10.1111/j.1365-2230.2008.02882.x. Epub 2008 Jul 4. No abstract available.

PMID:
18627387
3.

Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.

Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K.

Tumori. 2004 Jan-Feb;90(1):40-3.

PMID:
15143970
4.

Sensitization of chemotherapy by anti-HER.

Kataoka A, Ishida M, Murakami S, Ohno S.

Breast Cancer. 2004;11(2):105-15. Review.

PMID:
15550854
5.

EGFR inhibitor-associated acneiform folliculitis: assessment and management.

Duvic M.

Am J Clin Dermatol. 2008;9(5):285-94. Review.

PMID:
18717603
6.

Controversies in the use of adjuvant trastuzumab (Herceptin).

Chowdhury S, Pickering L, Ellis P.

J Br Menopause Soc. 2006 Dec;12(4):172-4. Review.

PMID:
17178019
7.

[Cutaneous side effects of EGF receptor inhibitors].

Nassar D, Soutou B, Aractingi S.

Bull Cancer. 2009 Dec;96 Suppl:S85-91. doi: 10.1684/bdc.2009.1000. French.

PMID:
20034874
8.

Trastuzumab and breast cancer: developments and current status.

Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, Maehara Y.

Int J Clin Oncol. 2006 Jun;11(3):199-208. Review.

PMID:
16850126
9.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.

PMID:
21172893
10.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

Kabe KL, Kolesar JM.

Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. Review.

PMID:
16522889
11.

[Tykerb for breast cancer].

Suzuki Y, Saito Y, Okamura T, Tokuda Y.

Gan To Kagaku Ryoho. 2011 Jun;38(6):892-5. Review. Japanese.

PMID:
21677477
12.

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

Cancer. 2007 Sep 1;110(5):965-72.

13.

[Clinical implications of trastuzumab].

Saeki T, Takashima S.

Gan To Kagaku Ryoho. 2003 Aug;30(8):1094-9. Review. Japanese.

PMID:
12938263
14.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
15.

Efficacy and safety of trastuzumab.

Jones RL, Smith IE.

Expert Opin Drug Saf. 2004 Jul;3(4):317-27. Review.

PMID:
15268649
16.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Yeon CH, Pegram MD.

Invest New Drugs. 2005 Oct;23(5):391-409. Review.

PMID:
16133791
17.
18.

Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.

Oliveras-Ferraros C, Vazquez-Martin A, CufĂ­ S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA.

Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9. doi: 10.1016/j.bbrc.2011.03.039. Epub 2011 Mar 21.

PMID:
21402055
19.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA.

Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. Review.

PMID:
10482195
20.

Supplemental Content

Support Center